Ioannis Vizirianakis

Prof. Ioannis Vizirianakis

Laboratory of Pharmacology, Department of Pharmaceutical Sciences, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece
orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2009 in IUBMB Life
Verified
Journal Article
Open access
PDF file
ATAsterios Tsiftsoglou
Asterios Tsiftsoglou
Ioannis VizirianakisIoannis Vizirianakis
Ioannis Vizirianakis
John StrouboulisJohn Strouboulis
John Strouboulis
Human erythropoiesis is a complex multistep developmental process that begins at the level of pluripotent hematopoietic stem cells (HSCs) at bone marrow microenvironment (HSCs niche) and terminates with the production of erythrocytes (RBCs). This review covers the basic and contemporary aspects of erythropoiesis. These include the: (a) cell‐lineage restricted pathways of differentiation originated from HSCs and going downward toward the blood cell development; (b) model systems employed to study erythropoiesis in culture (erythroleukemia cell lines and embryonic stem cells) and in vivo (knockout animals: avian, mice, zebrafish, and xenopus); (c) key regulators of erythropoiesis (iron, hypoxia, stress, and growth factors); (d) signaling pathways operating at hematopoietic stem cell niche for homeostatic regulation of self renewal (SCF/c‐kit receptor, Wnt, Notch, and Hox) and for erythroid differentiation (HIF and EpoR). Furthermore, this review presents the mechanisms through which transcriptional factors (GATA‐1, FOG‐1, TAL‐1/SCL/MO2/Ldb1/E2A, EKLF, Gfi‐1b, and BCL11A) and miRNAs regulate gene pattern expression during erythroid differentiation. New insights regarding the transcriptional regulation of α‐ and β‐globin gene clusters were also presented. Emphasis was also given on (i) the developmental program of erythropoiesis, which consists of commitment to terminal erythroid maturation and hemoglobin production, (two closely coordinated events of erythropoieis) and (ii) the capacity of human embryonic and umbilical cord blood (UCB) stem cells to differentiate and produce RBCs in culture with highly selective media. These most recent developments will eventually permit customized red blood cell production needed for transfusion. © 2009 IUBMB IUBMB Life 61(8): 800–830, 2009

3 January 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TVTheofanis Vavilis
Theofanis Vavilis
ESEleni Stamoula
Eleni Stamoula
AAAlexandra Ainatzoglou
Alexandra Ainatzoglou
ASAthanasios Sachinidis
Athanasios Sachinidis
MLMalamatenia Lamprinou
Malamatenia Lamprinou
Ioannis VizirianakisIoannis Vizirianakis
Ioannis Vizirianakis
Protein replacement therapy is an umbrella term used for medical treatments that aim to substitute or replenish specific protein deficiencies that result either from the protein being absent or non-functional due to mutations in affected patients. Traditionally, such an approach requires a well characterized but arduous and expensive protein production procedure that employs in vitro expression and translation of the pharmaceutical protein in host cells, followed by extensive purification steps. In the wake of the SARS-CoV-2 pandemic, mRNA-based pharmaceuticals were recruited to achieve rapid in vivo production of antigens, proving that the in vivo translation of exogenously administered mRNA is nowadays a viable therapeutic option. In addition, the urgency of the situation and worldwide demand for mRNA-based medicine has led to an evolution in relevant technologies, such as in vitro transcription and nanolipid carriers. In this review, we present preclinical and clinical applications of mRNA as a tool for protein replacement therapy, alongside with information pertaining to the manufacture of modified mRNA through in vitro transcription, carriers employed for its intracellular delivery and critical quality attributes pertaining to the finished product.

1 December 2003 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
ATAsterios Tsiftsoglou
Asterios Tsiftsoglou
IPIoannis S Pappas
Ioannis S Pappas
Ioannis VizirianakisIoannis Vizirianakis
Ioannis Vizirianakis

1 July 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MFMaria Filippousi
Maria Filippousi
STStuart Turner
Stuart Turner
Karen LeusKaren Leus
Karen Leus
Panoraia I. SiafakaPanoraia I. Siafaka
Panoraia I. Siafaka
ETEirini D. Tseligka
Eirini D. Tseligka
GTGustaaf Van Tendeloo
Gustaaf Van Tendeloo

12 May 2014 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
DFDimitrios G. Fatouros
Dimitrios G. Fatouros
Dimitrios A. LamprouDimitrios A. Lamprou
Dimitrios A. Lamprou
Andrew UrquhartAndrew Urquhart
Andrew Urquhart
Spyros YannopoulosSpyros Yannopoulos
Spyros Yannopoulos
Ioannis VizirianakisIoannis Vizirianakis
Ioannis Vizirianakis
Sotirios KoutsopoulosSotirios Koutsopoulos
Sotirios Koutsopoulos
Amphiphilic self-assembling peptides are functional materials, which, depending on the amino acid sequence, the peptide length, and the physicochemical conditions, form a variety of nanostructures including nanovesicles, nanotubes, and nanovalves. We designed lipid-like peptides with an aspartic acid or lysine hydrophilic head and a hydrophobic tail composed of six alanines (i.e., ac-A6K-CONH2, KA6-CONH2, ac-A6D-COOH, and DA6-COOH). The resulting novel peptides have a length similar to biological lipids and form nanovesicles at physiological conditions. AFM microscopy and light scattering analyses of the positively charged lipid-like ac-A6K-CONH2, KA6-CONH2 peptide formulations showed individual nanovesicles. The negatively charged ac-A6D-COOH and DA6-COOH peptides self-assembled into nanovesicles that formed clusters that upon drying were organized into necklace-like formations of nanovesicles. Encapsulation of probe molecules and release studies through the peptide bilayer suggest that peptide nanovesicles may be good candidates for sustained release of pharmaceutically active hydrophilic and hydrophobic compounds. Lipid-like peptide nanovesicles represent a paradigm shifting system that may complement liposomes for the delivery of diagnostic and therapeutic agents.

26 April 2019 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
Christina KaravasiliChristina Karavasili
Christina Karavasili
DADimitrios A. Andreadis
Dimitrios A. Andreadis
OKOrestis L Katsamenis
Orestis L Katsamenis
EPEmmanuel Panteris
Emmanuel Panteris
PAPinelopi Anastasiadou
Pinelopi Anastasiadou
DFDimitrios Fatouros
Dimitrios Fatouros